Trudeau Institute creates TICRO to expand the scope of biomedical research

The Trudeau Institute announced today that it has expanded the scope of its biomedical research by creating a contract research organization (CRO), the Trudeau Institute Contract Research Organization (TICRO). The Institute is responding to the drug development industry's increased reliance on CROs for specialty research in order to reduce the costs and delays associated with the development of new vaccines and therapeutics.

As world-renowned experts in the study of immunology and infectious disease using animal models, Trudeau scientists will now offer their expertise and models to the biopharmaceutical industry through TICRO. TICRO will provide project-specific infectious disease expertise to biopharmaceutical companies and academic researchers, assist clients with the design and execution of efficient studies with well-defined endpoints, and help accelerate the drug development process.

In offering contract research services, the Institute hopes to develop translational research partnerships with biotech and pharmaceutical companies and to help bring new therapeutics to patients safely and more efficiently.

Dr. Dawn Jelley-Gibbs has been appointed senior CRO program manager for TICRO and is working with the Institute's management team to develop and execute TICRO's scientific program. Jelley-Gibbs earned a B.S. in biology and chemistry in 1993 from the State University of New York at Plattsburgh and a Ph.D. in microbiology, immunology and molecular genetics in 1998 from Albany Medical College. She did her postdoctoral training with Dr. Susan L. Swain at the Trudeau Institute and joined the Institute's faculty in 2005 as a research assistant member.